Uso del rituximab(anticuerpo monoclonal anti-CD20) en lupus eritematoso sistémico refractario a tratamiento: Caso clínico / Rituximab (anti-CD20 monoclonal antibody) for refractory systemic lupus erythematosus: Report of one case
Rev. méd. Chile
;
133(6): 681-684, jun. 2005.
Article
in Spanish
| LILACS
| ID: lil-429123
ABSTRACT
New therapeutic approaches that include depletion of B cells using rituximab, a chimeric monoclonal antibody directed against the B cell specific antigen CD-20 have been developed for the treatment of systemic lupus erythematosus (SLE). We report the case of a 18 years old girl with SLE that did not respond and experienced adverse effects with the use of hydroxycloroquine, methotrexate, mycophenolate mofetil, azathioprine and high-dose steroids. Rituximab was given weekly at 375 mg/m2 for four doses. The drug was well tolerated and the patient had no adverse reactions. She remains asymptomatic three months later.
Full text:
Available
Index:
LILACS (Americas)
Main subject:
Immunologic Factors
/
Lupus Erythematosus, Systemic
/
Antibodies, Monoclonal
Limits:
Adolescent
/
Female
/
Humans
Language:
Spanish
Journal:
Rev. méd. Chile
Journal subject:
Medicine
Year:
2005
Type:
Article
Affiliation country:
Chile
Institution/Affiliation country:
Clínica Las Condes/CL
/
Universidad de Chile/CL
Similar
MEDLINE
...
LILACS
LIS